Format

Send to

Choose Destination
PLoS One. 2015 Jan 30;10(1):e0117334. doi: 10.1371/journal.pone.0117334. eCollection 2015.

Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C.

Author information

1
HEOR Ltd, Singleton Court Business Park, Monmouth, Wales, United Kingdom; Swansea Centre for Health Economics, School of Human & Health Sciences, Swansea University, Wales, United Kingdom.
2
HEOR Ltd, Singleton Court Business Park, Monmouth, Wales, United Kingdom.
3
Global Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
4
Bristol-Myers Squibb, Uxbridge, Middlesex, United Kingdom.

Abstract

INTRODUCTION:

Hepatitis C virus (HCV) infection is one of the principle causes of chronic liver disease. Successful treatment significantly decreases the risk of hepatic morbidity and mortality. Current standard of care achieves sustained virologic response (SVR) rates of 40-80%; however, the HCV therapy landscape is rapidly evolving. The objective of this study was to quantify the clinical and economic benefit associated with increasing levels of SVR.

METHODS:

A published Markov model (MONARCH) that simulates the natural history of hepatitis C over a lifetime horizon was used. Discounted and non-discounted life-years (LYs), quality-adjusted life-years (QALYs) and cost of complication management were estimated for various plausible SVR rates. To demonstrate the robustness of projections obtained, the model was validated to ten UK-specific HCV studies.

RESULTS:

QALY estimates ranged from 18.0 years for those treated successfully in fibrosis stage F0 to 7.5 years (discounted) for patients in fibrosis stage F4 who remain untreated. Predicted QALY gains per 10% improvement in SVR ranged from 0.23 (F0) to 0.64 (F4) and 0.58 (F0) to 1.35 (F4) in 40 year old patients (discounted and non-discounted results respectively). In those aged 40, projected discounted HCV-related costs are minimised with successful treatment in F0/F1 (at approximately £ 300), increasing to £ 49,300 in F4 patients who remain untreated. Validation of the model to published UK cost-effectiveness studies produce R2 goodness of fit statistics of 0.988, 0.978 and of 0.973 for total costs, QALYs and incremental cost effectiveness ratios, respectively.

CONCLUSION:

Projecting the long-term clinical and economic consequences associated with chronic hepatitis C is a necessary requirement for the evaluation of new treatments. The principle analysis demonstrates the significant impact on expected costs, LYs and QALYs associated with increasing SVR. A validation analysis demonstrated the robustness of the results reported.

PMID:
25635922
PMCID:
PMC4311930
DOI:
10.1371/journal.pone.0117334
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center